AN2 Therapeutics, Inc. — Company profile
Healthcare · Biotechnology · United States
Last price 4.53 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 170.95M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
AN2 Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics. The company’s initial candidate includes epetraborole, which is phase 3 clinical trial as a once-daily oral treatment for patients with non-tuberculous mycobacterial lung disease, as well as studying for the treatment of acute melioidosis. It also develops AN2-502998 (AN15368), an investigational, boron-based small molecule in development for the treatment of chronic Chagas disease that is in preclinical trials; and has various research programs targeting the development of novel compounds in oncology and infectious disease based on its boron chemistry platform. It has a license agreement with Anacor Pharmaceuticals, Inc. to use, develop, manufacture, commercialize compounds and products, including epetraborole for the treatment, diagnosis, or prevention of various human diseases; and Brii Biosciences Limited to research, develop, manufacture, and commercialize compounds and products comprising epetraborole in China, Hong Kong, Taiwan, and Macau for the diagnosis, treatment, and prevention of human diseases; and GSK plc for the development of new therapies for TB. AN2 Therapeutics, Inc. was incorporated in 2017 and is headquartered in Menlo Park, California.
Details
| Name | AN2 Therapeutics, Inc. |
| Sector | Healthcare |
| Industry | Biotechnology |
| Employees | 21 |
| Founded | 2017 |
| Ipo Date | 2022-03-25 |
| Ceo | Eric Easom |
| Country | United States |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Ipo Price | 15.00 |
| Isin | US0373261058 |
| Cusip | 037326105 |
| Cik | 1880438 |
| Sic | 2834 |
| Stock Type | Common Stock |
Key executives
| Name | Title |
|---|---|
| Eric E. Easom | Co-Founder, Chief Executive Officer, President and Chairman of the Board |
| Joseph S. Zakrzewski | Co-Founder and Independent Director |
| Lucy O. Day CPA | Chief Financial Officer, and Principal Financial Officer |
| Joshua M. Eizen J.D. | Chief Legal Officer, Chief Operating Officer and Corporate Secretary |
| Dr. George Harrison Talbot FACP, M.D. | Co-Founder and Senior Clinical Advisor |
| Dr. Michael R. K. Alley Ph.D. | Co-founder and Head of Biology |
| Sarah Williams | Vice President of Controller and Principal Accounting Officer |
| Dr. Sanjay Chanda Ph.D. | Chief Development Officer |
| Vince Hernandez | Head of Research |
| Dr. Cameron Trenor M.D. | Chief Medical Officer |
Contact
| Address | 1300 El Camino Real, Suite 100, Menlo Park, California 94025, United States |
| Phone | 650 331 9090 |
| Website | https://www.an2therapeutics.com |